Indacaterol and glycopyrrolate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
Line 246: Line 246:
[[Indacaterol]] serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing ranged from 40 to 56 hours which is consistent with the observed time to steady-state of approximately 12 to 15 days.
[[Indacaterol]] serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing ranged from 40 to 56 hours which is consistent with the observed time to steady-state of approximately 12 to 15 days.


''[[Glycopyrrolate]]'': Renal elimination of parent drug accounts for about 60% to 70% of total clearance of systemically available [[glycopyrrolate]] whereas non-renal clearance processes account for about 30% to 40%. Biliary clearance contributes to the non-renal clearance, but the majority of non-[[renal clearance]] is thought to be due to [[metabolism]].
''[[Glycopyrrolate]]'': Renal elimination of parent drug accounts for about 60% to 70% of total clearance of systemically available [[glycopyrrolate]] whereas non-renal clearance processes account for about 30% to 40%. Biliary clearance contributes to the non-[[renal clearance]], but the majority of non-[[renal clearance]] is thought to be due to [[metabolism]].


Following inhalation of single and repeated once-daily doses between 62.4 mcg and 249.6 mcg [[glycopyrrolate]] by healthy volunteers and patients with [[COPD]], mean [[renal clearance]] of [[glycopyrrolate]] was in the range of 17.4 L/h and 24.4 L/h. Active tubular secretion contributes to the renal elimination of [[glycopyrrolate]].
Following inhalation of single and repeated once-daily doses between 62.4 mcg and 249.6 mcg [[glycopyrrolate]] by healthy volunteers and patients with [[COPD]], mean [[renal clearance]] of [[glycopyrrolate]] was in the range of 17.4 L/h and 24.4 L/h. Active tubular secretion contributes to the renal elimination of [[glycopyrrolate]].
Line 258: Line 258:
No specific drug-drug interaction studies were conducted with [[indacaterol]] and [[glycopyrrolate]]. Information on the potential for interactions for [[indacaterol]] and [[glycopyrrolate]] is based on the potential for each of its 2 [[monotherapy]] components.
No specific drug-drug interaction studies were conducted with [[indacaterol]] and [[glycopyrrolate]]. Information on the potential for interactions for [[indacaterol]] and [[glycopyrrolate]] is based on the potential for each of its 2 [[monotherapy]] components.


''Effect of co-administered drugs on indacaterol]] and [[glycopyrrolate]] exposure''':
''Effect of co-administered drugs on [[indacaterol]] and [[glycopyrrolate]] exposure'':


''[[Indacaterol]]'':  
''[[Indacaterol]]'':  


Inhibitors of [[Cytochrome P450 3A4]] and [[P-gp]] Efflux Transporter: Drug interaction studies were carried out using potent and specific inhibitors of [[CYP3A4]] and [[P-gp]] (i.e., [[ketoconazole]], [[erythromycin]], [[verapamil]] and [[ritonavir]]). Coadministration of [[indacaterol]] 300 mcg (single dose) with [[verapamil]] (80 mg 3 times a day for 4 days) showed 2-fold increase in [[indacaterol]] AUC0-24h, and 1.5-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] inhalation powder 300 mcg (single dose) with [[erythromycin]] (400 mg 4 times a day for 7 days) showed a 1.4-fold increase in [[indacaterol]] [[AUC]]0-24h, and 1.2-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] inhalation powder 300 mcg (single dose) with [[ketoconazole]] (200 mg twice-daily for 7 days) caused a 1.9-fold increase in [[indacaterol]] [[AUC]]0-24h, and 1.3-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] 300 mcg (single dose) with [[ritonavir]] (300 mg twice-daily for 7.5 days) resulted in a 1.7-fold increase in [[indacaterol]] [[AUC]]0-24h whereas [[indacaterol]] [[Cmax]] was unaffected.
Inhibitors of [[Cytochrome P450 3A4]] and [[P-gp]] Efflux Transporter: Drug interaction studies were carried out using potent and specific inhibitors of [[CYP3A4]] and [[P-gp]] (i.e., [[ketoconazole]], [[erythromycin]], [[verapamil]] and [[ritonavir]]). Coadministration of [[indacaterol]] 300 mcg (single dose) with [[verapamil]] (80 mg 3 times a day for 4 days) showed 2-fold increase in [[indacaterol]] [[AUC]]0-24h, and 1.5-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] inhalation powder 300 mcg (single dose) with [[erythromycin]] (400 mg 4 times a day for 7 days) showed a 1.4-fold increase in [[indacaterol]] [[AUC]]0-24h, and 1.2-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] inhalation powder 300 mcg (single dose) with [[ketoconazole]] (200 mg twice-daily for 7 days) caused a 1.9-fold increase in [[indacaterol]] [[AUC]]0-24h, and 1.3-fold increase in [[indacaterol]] [[Cmax]]. Coadministration of [[indacaterol]] 300 mcg (single dose) with [[ritonavir]] (300 mg twice-daily for 7.5 days) resulted in a 1.7-fold increase in [[indacaterol]] [[AUC]]0-24h whereas [[indacaterol]] [[Cmax]] was unaffected.


''[[Glycopyrrolate]]'':
''[[Glycopyrrolate]]'': [[Cimetidine]] or Other Inhibitors of Organic Cationic Transport: In a clinical study in healthy volunteers, [[cimetidine]], an inhibitor of organic cation transport which is thought to contribute to the renal excretion of [[glycopyrrolate]], increased total exposure ([[AUC]]) to [[glycopyrrolate]] by 22% and decreased [[renal clearance]] by 23%.
 
[[Cimetidine]] or Other Inhibitors of Organic Cationic Transport: In a clinical study in healthy volunteers, [[cimetidine]], an inhibitor of organic cation transport which is thought to contribute to the renal excretion of [[glycopyrrolate]], increased total exposure ([[AUC]]) to [[glycopyrrolate]] by 22% and decreased [[renal clearance]] by 23%.


''Effect of [[indacaterol]] and [[glycopyrrolate]] on co-administered drugs exposure'':
''Effect of [[indacaterol]] and [[glycopyrrolate]] on co-administered drugs exposure'':
Line 274: Line 272:
''[[Indacaterol]]'': In vitro investigations indicated that [[indacaterol]] has negligible potential to cause metabolic interactions with medications (by inhibition or induction of [[cytochrome P450]] [[enzymes]], or induction of [[UGT1A1]]) at the systemic exposure levels achieved in clinical practice. In vitro investigation furthermore indicated that, in vivo, [[indacaterol]] is unlikely to significantly inhibit transporter proteins such as [[P-gp]], MRP2, BCRP, the cationic substrate transporters hOCT1 and hOCT2, and the human multidrug and toxin extrusion transporters hMATE1 and hMATE2K, and that [[indacaterol]] has negligible potential to induce [[P-gp]] or MRP2.
''[[Indacaterol]]'': In vitro investigations indicated that [[indacaterol]] has negligible potential to cause metabolic interactions with medications (by inhibition or induction of [[cytochrome P450]] [[enzymes]], or induction of [[UGT1A1]]) at the systemic exposure levels achieved in clinical practice. In vitro investigation furthermore indicated that, in vivo, [[indacaterol]] is unlikely to significantly inhibit transporter proteins such as [[P-gp]], MRP2, BCRP, the cationic substrate transporters hOCT1 and hOCT2, and the human multidrug and toxin extrusion transporters hMATE1 and hMATE2K, and that [[indacaterol]] has negligible potential to induce [[P-gp]] or MRP2.


''[[Glycopyrrolate]]'': In vitro inhibition studies demonstrated that [[glycopyrrolate]] has no relevant capacity to inhibit [[CYP1A2]], [[CYP2A6]], [[CYP2C8]], CYP2C9, CYP2C19, [[CYP2D6]], [[CYP2E1]] or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OATP1B1, OATP1B3, OAT1, OAT3, OCT1 or OCT2. In vitro [[enzyme]] induction studies did not indicate a clinically relevant induction by [[glycopyrrolate]] for any of the [[cytochrome P450]] isoenzymes tested as well as for [[UGT1A1]] and the transporters MDR1 and MRP2.
''[[Glycopyrrolate]]'': In vitro inhibition studies demonstrated that [[glycopyrrolate]] has no relevant capacity to inhibit [[CYP1A2]], [[CYP2A6]], [[CYP2C8]], [[CYP2C9]], [[CYP2C19]], [[CYP2D6]], [[CYP2E1]] or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OATP1B1, OATP1B3, OAT1, OAT3, OCT1 or OCT2. In vitro [[enzyme]] induction studies did not indicate a clinically relevant induction by [[glycopyrrolate]] for any of the [[cytochrome P450]] isoenzymes tested as well as for [[UGT1A1]] and the transporters MDR1 and MRP2.


'''Specific Populations''':
'''Specific Populations''':
Line 310: Line 308:
''[[Glycopyrrolate]]'': [[Glycopyrrolate]] produced no treatment-related increases in the incidence of [[tumors]] in a 2-year inhalation study in Wistar rats at inhaled doses up to 0.56 mg/kg/day (approximately 170 times the MRHD in adults on an [[AUC]] basis). A 26-week oral (gavage) study in male and female TgrasH2 mice that received [[glycopyrrolate]] at doses up to 93.8 and 125.1 mg/kg/day, respectively, did not show any evidence of tumorigenicity.
''[[Glycopyrrolate]]'': [[Glycopyrrolate]] produced no treatment-related increases in the incidence of [[tumors]] in a 2-year inhalation study in Wistar rats at inhaled doses up to 0.56 mg/kg/day (approximately 170 times the MRHD in adults on an [[AUC]] basis). A 26-week oral (gavage) study in male and female TgrasH2 mice that received [[glycopyrrolate]] at doses up to 93.8 and 125.1 mg/kg/day, respectively, did not show any evidence of tumorigenicity.
[[Glycopyrrolate]] tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro human lymphocyte [[chromosomal aberration]] assay, and in vivo rat bone marrow [[micronucleus]] assay.
[[Glycopyrrolate]] tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro human lymphocyte [[chromosomal aberration]] assay, and in vivo rat bone marrow [[micronucleus]] assay.
Impairment of [[fertility]] was observed in male and female rats at a [[subcutaneous]] dose of 1.88 mg/kg/day (approximately 1900 and 1100 times the MRHD in adults on an [[AUC]] basis, respectively) based upon findings of decreased [[corpora lutea]], implantation sites and live fetuses. No effects on [[fertility]] and reproductive performance in male and female rats were observed at a [[subcutaneous]] dose of 0.63 mg/kg/day (approximately 350 times the MRHD in adults on an [[AUC]] basis).
Impairment of [[fertility]] was observed in male and female rats at a [[subcutaneous]] dose of 1.88 mg/kg/day (approximately 1900 and 1100 times the MRHD in adults on an [[AUC]] basis, respectively) based upon findings of decreased corpora lutea, implantation sites and live fetuses. No effects on [[fertility]] and reproductive performance in male and female rats were observed at a [[subcutaneous]] dose of 0.63 mg/kg/day (approximately 350 times the MRHD in adults on an [[AUC]] basis).


'''Animal Toxicology''':
'''Animal Toxicology''':
Line 334: Line 332:
The 12-week trials evaluated the efficacy of 2038 subjects that had a clinical diagnosis of [[COPD]], were 40 years of age or older, had a history of smoking greater than 10 pack-years, had a post-[[albuterol]] [[FEV1]] greater than or equal to 30% and less than 80% of predicted normal values, had a ratio of [[FEV1]]/[[FVC]] of less than 0.7, and were symptomatic as determined by a Modified Medical Research Council (mMRC) score greater than or equal to 2. Of the 2038 subjects included in the efficacy analysis, 63% were male and 91% were Caucasian. They had a mean age of 63 years and an average smoking history of 47 pack-years, with 52% identified as current smokers, and 46% used concomitant inhaled [[corticosteroids]]. At screening, the mean post-[[bronchodilator]] percent predicted [[FEV1]] was 55% (range: 29% to 79%), the mean post-[[bronchodilator]] [[FEV1]]/[[FVC]] ratio was 50% (range: 19% to 71%), and the mean percent reversibility was 23% (range: 0% to 144%).
The 12-week trials evaluated the efficacy of 2038 subjects that had a clinical diagnosis of [[COPD]], were 40 years of age or older, had a history of smoking greater than 10 pack-years, had a post-[[albuterol]] [[FEV1]] greater than or equal to 30% and less than 80% of predicted normal values, had a ratio of [[FEV1]]/[[FVC]] of less than 0.7, and were symptomatic as determined by a Modified Medical Research Council (mMRC) score greater than or equal to 2. Of the 2038 subjects included in the efficacy analysis, 63% were male and 91% were Caucasian. They had a mean age of 63 years and an average smoking history of 47 pack-years, with 52% identified as current smokers, and 46% used concomitant inhaled [[corticosteroids]]. At screening, the mean post-[[bronchodilator]] percent predicted [[FEV1]] was 55% (range: 29% to 79%), the mean post-[[bronchodilator]] [[FEV1]]/[[FVC]] ratio was 50% (range: 19% to 71%), and the mean percent reversibility was 23% (range: 0% to 144%).


Trial 1 and Trial 2 evaluated [[indacaterol]] and [[glycopyrrolate]] 27.5 mcg/15.6 mcg twice-daily (BID), [[indacaterol]] 27.5 mcg BID, [[glycopyrrolate]] 15.6 mcg BID, and placebo BID. The primary endpoint was the change from baseline in [[FEV1]] [[AUC]]0-12h following the morning dose at Day 85 (defined as the mean FEV1 change from baseline over 0 to 12 hours divided by 12 hours) compared with placebo, [[glycopyrrolate]] 15.6 mcg BID, and [[indacaterol]] 27.5 mcg BID. The comparison of [[indacaterol]] and [[glycopyrrolate]] with [[indacaterol]] 27.5 mcg and [[glycopyrrolate]] 15.6 mcg was assessed to evaluate the contribution of the individual comparators to [[indacaterol]] and [[glycopyrrolate]]. In both trials, [[indacaterol]] and [[glycopyrrolate]] demonstrated a larger increase in mean change from baseline in [[FEV1]] [[AUC]]0-12h compared to placebo, [[indacaterol]] 27.5 mcg BID, and [[glycopyrrolate]] 15.6 mcg BID (see Table 2).
Trial 1 and Trial 2 evaluated [[indacaterol]] and [[glycopyrrolate]] 27.5 mcg/15.6 mcg twice-daily (BID), [[indacaterol]] 27.5 mcg BID, [[glycopyrrolate]] 15.6 mcg BID, and placebo BID. The primary endpoint was the change from baseline in [[FEV1]] [[AUC]]0-12h following the morning dose at Day 85 (defined as the mean [[FEV1]] change from baseline over 0 to 12 hours divided by 12 hours) compared with placebo, [[glycopyrrolate]] 15.6 mcg BID, and [[indacaterol]] 27.5 mcg BID. The comparison of [[indacaterol]] and [[glycopyrrolate]] with [[indacaterol]] 27.5 mcg and [[glycopyrrolate]] 15.6 mcg was assessed to evaluate the contribution of the individual comparators to [[indacaterol]] and [[glycopyrrolate]]. In both trials, [[indacaterol]] and [[glycopyrrolate]] demonstrated a larger increase in mean change from baseline in [[FEV1]] [[AUC]]0-12h compared to placebo, [[indacaterol]] 27.5 mcg BID, and [[glycopyrrolate]] 15.6 mcg BID (see Table 2).
[[File:Indacaterol and glycopyrrolate T2.JPG|thumb|none|400px|This image is provided by the National Library of Medicine]]
[[File:Indacaterol and glycopyrrolate T2.JPG|thumb|none|400px|This image is provided by the National Library of Medicine]]


Latest revision as of 19:32, 28 July 2017

Indacaterol and glycopyrrolate
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Allison Tu [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

ASTHMA-RELATED DEATH
See full prescribing information for complete Boxed Warning.
  • Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death.
  • Data from a large, placebo-controlled U.S. study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol.
  • This finding with salmeterol is considered a class effect of all LABAs, including indacaterol, one of the active ingredients in indacaterol and glycopyrrolate.
  • The safety and efficacy of indacaterol and glycopyrrolate in patients with asthma have not been established. Indacaterol and glycopyrrolate is not indicated for the treatment of asthma.

Overview

Indacaterol and glycopyrrolate is a combination of a long-acting beta2-adrenergic agonist and an anticholinergic that is FDA approved for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. There is a Black Box Warning for this drug as shown here. Common adverse reactions include cough.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indacaterol and glycopyrrolate is indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Indacaterol and glycopyrrolate is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

Dosing Information

  • The recommended dosage of indacaterol and glycopyrrolate is the inhalation of the contents of one indacaterol and glycopyrrolate capsule twice-daily using the NEOHALER device.
  • No dosage adjustment is required for geriatric patients, patients with mild and moderate hepatic impairment, or patients with mild to moderate renal impairment.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of indacaterol and glycopyrrolate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of indacaterol and glycopyrrolate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Indacaterol and glycopyrrolate FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Indacaterol and glycopyrrolate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Indacaterol and glycopyrrolate in pediatric patients.

Contraindications

Warnings

ASTHMA-RELATED DEATH
See full prescribing information for complete Boxed Warning.
  • Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death.
  • Data from a large, placebo-controlled U.S. study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol.
  • This finding with salmeterol is considered a class effect of all LABAs, including indacaterol, one of the active ingredients in indacaterol and glycopyrrolate.
  • The safety and efficacy of indacaterol and glycopyrrolate in patients with asthma have not been established. Indacaterol and glycopyrrolate is not indicated for the treatment of asthma.

Adverse Reactions

Clinical Trials Experience

LABAs, such as indacaterol, one of the active ingredients in indacaterol and glycopyrrolate, increase the risk of asthma-related death. Indacaterol and glycopyrrolate is not indicated for the treatment of asthma.

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.

The indacaterol and glycopyrrolate safety database included 2654 subjects with COPD in two 12-week lung function trials and one 52-week long-term safety study. A total of 712 subjects received treatment with indacaterol and glycopyrrolate 27.5 mcg/15.6 mcg twice daily (BID). The safety data described below are based on the two 12-week trials and the one 52-week trial.

12-Week Trials:

The incidence of adverse reactions associated with indacaterol and glycopyrrolate in Table 1 is based on two 12-week, placebo-controlled trials (Trials 1 and 2; N=1,001 and N=1,042 respectively). Of the 2040 subjects, 63% were male and 91% were Caucasian. They had a mean age of 63 years and an average smoking history of 47 pack-years, with 52% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV1) was 55% (range: 29% to 79%), the mean post-bronchodilator FEV1/forced vital capacity (FVC) ratio was 50% (range: 19% to 71%), and the mean percent reversibility was 23% (range: 0% to 144%).

The most common adverse reaction (incidence greater than or equal to 2% and higher than placebo) was nasopharyngitis and hypertension.

The proportion of patients who discontinued treatment due to adverse reactions was 2.95% for the indacaterol and glycopyrrolate treated patients and 4.13% for placebo-treated patients.

Subjects received 1 dose twice-daily of the following: indacaterol and glycopyrrolate 27.5 mcg/15.6 mcg, indacaterol 27.5 mcg, glycopyrrolate 15.6 mcg, or placebo.

This image is provided by the National Library of Medicine

Other adverse reactions occurring more frequently with indacaterol and glycopyrrolate than with placebo, but with an incidence of less than 1% include dyspepsia, gastroenteritis, chest pain, fatigue, peripheral edema, rash/pruritus, insomnia, dizziness, bladder obstruction/urinary retention, atrial fibrillation, palpitations, tachycardia.

52-Week Trial:

In a long-term safety trial, 614 subjects were treated for up to 52 weeks with indacaterol/glycopyrrolate 27.5 mcg/15.6 mcg twice-daily, indacaterol/glycopyrrolate 27.5/31.2 mcg twice-daily or indacaterol 75 mcg once-daily. The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy trials described above. The adverse reactions reported in the long-term safety trial were consistent with those observed in the placebo-controlled trials of 12 weeks. Additional adverse reactions that occurred with a frequency greater than or equal to 2% in the group receiving indacaterol/glycopyrrolate 27.5 mcg/15.6 mcg twice-daily that exceeded the frequency of indacaterol 75 mcg once-daily in this trial were upper and lower respiratory tract infection, pneumonia, diarrhea, headache, gastroesophageal reflux disease, hyperglycemia, rhinitis.

Postmarketing Experience

The following additional adverse reactions of angioedema and dysphonia have been identified during worldwide post-approval use of indacaterol/glycopyrrolate at higher than the recommended dose. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Drug Interactions

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C Teratogenic Effects - Pregnancy Category C

There are no adequate and well-controlled studies with indacaterol and glycopyrrolate or its individual components, indacaterol and glycopyrrolate, in pregnant women. Animal reproduction studies were conducted with individual components, indacaterol and glycopyrrolate. Because animal reproduction studies are not always predictive of human response, indacaterol and glycopyrrolate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physician if they become pregnant while taking indacaterol and glycopyrrolate.

Indacaterol: Indacaterol was not teratogenic in Wistar rats and New Zealand rabbits at approximately 340 and 770 times, respectively, the MRHD in adults (on an AUC basis at maternal subcutaneous doses up to 1 mg/kg/day in rats and rabbits).

Glycopyrrolate: Glycopyrrolate was not teratogenic in Wistar rats or New Zealand White rabbits at approximately 1400 and 530 times, respectively, the MRHD in adults (on an AUC basis at maternal inhaled doses up to 3.83 mg/kg/day in rats and up to 4.4 mg/kg/day in rabbits).

Teratogenic Effects: Pregnancy Category C

There are no adequate and well-controlled studies with indacaterol and glycopyrrolate or its individual components, indacaterol and glycopyrrolate, in pregnant women. Animal reproduction studies were conducted with individual components, indacaterol and glycopyrrolate. Because animal reproduction studies are not always predictive of human response, indacaterol and glycopyrrolate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physician if they become pregnant while taking indacaterol and glycopyrrolate.

Indacaterol: Indacaterol was not teratogenic in Wistar rats and New Zealand rabbits at approximately 340 and 770 times, respectively, the MRHD in adults (on an AUC basis at maternal subcutaneous doses up to 1 mg/kg/day in rats and rabbits).

Glycopyrrolate: Glycopyrrolate was not teratogenic in Wistar rats or New Zealand White rabbits at approximately 1400 and 530 times, respectively, the MRHD in adults (on an AUC basis at maternal inhaled doses up to 3.83 mg/kg/day in rats and up to 4.4 mg/kg/day in rabbits).

Non-teratogenic Effects:

Indacaterol: There were no effects on perinatal and postnatal developments in rats at approximately 110 times the MRHD in adults (on an AUC basis at maternal subcutaneous doses up to 0.3 mg/kg/day).

Glycopyrrolate: There were no effects on perinatal and postnatal developments in rats at approximately 1100 times the MRHD in adults (on an AUC basis at maternal subcutaneous doses up to 1.88 mg/kg/day).
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Indacaterol and glycopyrrolate in women who are pregnant.

Labor and Delivery

There are no adequate and well-controlled human trials that have investigated the effects of indacaterol and glycopyrrolate during labor and delivery. Because beta-agonists may potentially interfere with uterine contractility, indacaterol and glycopyrrolate should be used during labor only if the potential benefit justifies the potential risk.

In human parturients undergoing Caesarean section, 86 minutes after a single intramuscular injection of 0.006 mg/kg glycopyrrolate, umbilical plasma concentrations were low.

Nursing Mothers

Indacaterol and Glycopyrrolate: It is not known whether indacaterol and glycopyrrolate is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when indacaterol and glycopyrrolate is administered to a nursing woman. Since there are no data from well-controlled human studies on the use of indacaterol and glycopyrrolate by nursing mothers, based on the data for the individual components, a decision should be made whether to discontinue nursing or to discontinue indacaterol and glycopyrrolate, taking into account the importance of indacaterol and glycopyrrolate to the mother.

Indacaterol: It is not known whether indacaterol is excreted in human breast milk. Indacaterol (including its metabolites) have been detected in the milk of lactating rats.

Glycopyrrolate: It is not known whether glycopyrrolate is excreted in human breast milk. Glycopyrrolate (including its metabolites) have been detected in the milk of lactating rats and reached up to 10-fold higher concentrations in the milk than in the blood of the dam.

Pediatric Use

Indacaterol and glycopyrrolate is not indicated for use in children. The safety and efficacy of indacaterol and glycopyrrolate in pediatric patients have not been established.

Geriatic Use

Based on available data, no adjustment of indacaterol and glycopyrrolate dosage in geriatric patients is warranted. Indacaterol and glycopyrrolate can be used at the recommended dose in elderly patients 75 years of age and older.

Of the total number of subjects in clinical studies of indacaterol and glycopyrrolate, 45% were aged 65 and older, while 11% were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Gender

There is no FDA guidance on the use of Indacaterol and glycopyrrolate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Indacaterol and glycopyrrolate with respect to specific racial populations.

Renal Impairment

Based on the pharmacokinetic characteristics of its monotherapy components, indacaterol and glycopyrrolate can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment (estimated GFR less than 30 mL/min/1.73 m2) or end-stage renal disease requiring dialysis, indacaterol and glycopyrrolate should be used if the expected benefit outweighs the potential risk since the systemic exposure to glycopyrrolate may be increased in this population.

Hepatic Impairment

Based on the pharmacokinetic characteristics of its monotherapy components, indacaterol and glycopyrrolate can be used at the recommended dose in patients with mild to moderate hepatic impairment. Studies in subjects with severe hepatic impairment have not been performed.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Indacaterol and glycopyrrolate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Indacaterol and glycopyrrolate in patients who are immunocompromised.

Administration and Monitoring

Administration

Indacaterold and glycopyrrolate is for oral inhalation only. Do not swallow Indacaterol and glycopyrrolate capsules, as the intended effects on the lungs will not be obtained. Indacaterol and glycopyrrolate capsules should only be used with the NEOHALER device. Indacaterol and glycopyrrolate should be administered at the same time of the day (1 capsule in the morning and 1 capsule in the evening) every day. More frequent administration or a greater number of inhalations (more than 1 capsule twice-daily) of indacaterol and glycopyrrolate is not recommended. Store indacaterol and glycopyrrolate capsules in the blister, and only remove IMMEDIATELY BEFORE USE with the NEOHALER device.

Monitoring

There is limited information regarding Indacaterol and glycopyrrolate Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Indacaterol and glycopyrrolate and IV administrations.

Overdosage

In COPD patients, doses of up to 600/124.8 mcg indacaterol and glycopyrrolate were inhaled over 2 weeks and there were no relevant effects on heart rate, QTc interval, blood glucose or serum potassium. There was an increase in ventricular ectopies after 14 days of dosing with 300/124.8 mcg and 600/124.8 mcg indacaterol and glycopyrrolate, but low prevalence and small patient numbers (N=49 and N=51 for 600/124.8 mcg and 300/124.8 mcg indacaterol and glycopyrrolate, respectively) precluded accurate analysis. In a total of four patients, non-sustained ventricular tachycardia was recorded, with the longest episode recorded being 9 beats (4 seconds).

In healthy volunteers, single dose administration of indacaterol and glycopyrrolate at up to a dose of 440/499.2 mcg indacaterol/glycopyrrolate was well-tolerated without clinically significant effects on the ECG, serum potassium or blood glucose.

Indacaterol and glycopyrrolate contains both indacaterol and glycopyrrolate; therefore, the risks associated with overdosage for the individual components described below apply to indacaterol and glycopyrrolate. Treatment of overdosage consists of discontinuation of indacaterol and glycopyrrolate together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. Cardiac monitoring is recommended in cases of overdosage.

Indacaterol: The potential signs and symptoms associated with overdosage of indacaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, vomiting, drowsiness, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of indacaterol.

In COPD patients, single doses of indacaterol 3000 mcg were associated with moderate increases in pulse rate, systolic blood pressure and QTc interval.

Glycopyrrolate: An overdose of glycopyrrolate may lead to anticholinergic signs and symptoms such as nausea, vomiting, dizziness, lightheadedness, blurred vision, increased intraocular pressure (causing pain, vision disturbances or reddening of the eye), obstipation or difficulties in voiding.

In COPD patients, repeated orally inhaled administration of glycopyrrolate at total doses of 124.8 mcg and 249.6 mcg once-daily for 28 days were well tolerated.

Peak plasma levels and total systemic exposure following intravenous administration of 150 mcg glycopyrrolate (equivalent to 120 mcg active moiety) in healthy volunteers were respectively about 270-fold and 13-fold higher than the peak and total systemic exposure at steady-state achieved with the recommended daily dose of 31.2 mcg of glycopyrrolate (i.e., 15.6 mcg glycopyrrolate twice-daily) and were well tolerated.

Pharmacology

Indacaterol and glycopyrrolate
Combination of
Indacaterol Ultra-long-acting beta-adrenoceptor agonist
Glycopyrronium bromide Muscarinic anticholinergic
Identifiers
CAS number 444313-53-5
ATC code R03AL04
PubChem 11564052
Therapeutic considerations
Pregnancy cat.

B3(AU)

Legal status

Prescription Only (S4)(AU) POM(UK) Template:Unicode Prescription only

Routes Inhalation only

Mechanism of Action

Indacaterol and glycopyrrolate contains both indacaterol and glycopyrrolate. The mechanisms of action described below for the individual components apply to indacaterol and glycopyrrolate. These drugs represent 2 different classes of medications (a LABA and an anticholinergic) that have different and additive effects on clinical and physiological indices.

Indacaterol: Indacaterol is a long-acting beta2-adrenergic agonist (LABA). When inhaled, indacaterol acts locally in the lung as a bronchodilator. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-adrenergic receptors in the human heart comprising 10% to 50% of the total adrenergic receptors. The precise function of these receptors is not known, but their presence raises the possibility that even highly selective beta2-adrenergic agonists may have cardiac effects.

The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. The clinical significance of these findings is unknown.

Glycopyrrolate: Glycopyrrolate is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced broncho-constrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of glycopyrrolate is predominantly a site-specific effect.

Structure

Indacaterol maleate is a selective beta2-adrenergic agonist. Its chemical name is (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one maleate; its structural formula is:

This image is provided by the National Library of Medicine

Indacaterol maleate has a molecular weight of 508.56, and its empirical formula is C24H28N2O3 • C4H4O4. Indacaterol maleate is a white to very slightly grayish or very slightly yellowish powder. Indacaterol maleate is slightly soluble in ethanol and very slightly soluble in water.

Glycopyrrolate is chemically described as (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl) oxy]-1,1-dimethylpyrrolidinium bromide. This synthetic quaternary ammonium compound acts as a competitive antagonist at muscarinic acetylcholine receptors, also referred to as anticholinergic. Glycopyrrolate, C19H28BrNO3, is a white powder that is freely soluble in water and sparingly soluble in absolute ethanol. It has a molecular mass of 398.33. The structural formula is:

This image is provided by the National Library of Medicine

Pharmacodynamics

Cardiac Electrophysiology

The QTc interval was studied in TQT studies with indacaterol and glycopyrrolate and with each of the monotherapy components. The TQT studies with indacaterol and glycopyrrolate demonstrated that neither of the compounds had a relevant effect on the corrected QT interval at supratherapeutic and therapeutic doses (for glycopyrrolate only a supratherapeutic dose was tested).

In a randomized, partially-blinded, placebo- and positive-controlled, crossover TQT study in 84 healthy subjects a supratherapeutic dose of indacaterol and glycopyrrolate (indacaterol/glycopyrrolate 440/499.2 mcg) was administered. This is a 16/32 dose multiple compared to a single dose of the recommended 27.5/15.6 mcg twice-daily dosage of indacaterol and glycopyrrolate which resulted in exposure multiples for mean Cmax of 9.3 for indacaterol and 35.2 for glycopyrrolate compared to steady-state pharmacokinetics of indacaterol and glycopyrrolate 27.5/15.6 mcg twice-daily. The mean maximal change from baseline in QTcI compared to placebo was 8.70 msec (2-sided 90% CI 7.3, 10.1) at 30 minutes after dosing. Although a marginal QT effect of indacaterol and glycopyrrolate was observed at the supratherapeutirapeutic exposure.

Pharmacokinetics

Absorption

Following inhalation of indacaterol and glycopyrrolate, the median time to reach peak plasma concentrations of indacaterol and glycopyrrolate was achieved rapidly at approximately 15 minutes and 5 minutes, respectively.

The steady-state systemic exposure (AUC0-12h,ss; Cmax,ss) to indacaterol and glycopyrrolate is similar after the twice-daily inhalation of 2 (times 2) capsules of indacaterol and glycopyrrolate 27.5 mcg/15.6 mcg as compared to the twice-daily inhalation of the monotherapy products indacaterol 27.5 mcg (times 2) alone or glycopyrrolate 15.6 mcg (times 2) alone respectively.

Indacaterol: Absolute bioavailability of indacaterol after an inhalation dose was on average 43% to 45%. Systemic exposure results from a composite of pulmonary and intestine absorption. Indacaterol serum concentrations increased with repeated once-daily administration. Steady-state was achieved within 12 to 15 days. The mean accumulation ratio of indacaterol, i.e., AUC over the 24-hour dosing interval on Day 14 or Day 15 compared to Day 1, was in the range of 2.9 to 3.8 for once-daily inhaled doses between 75 mcg and 600 mcg.

Glycopyrrolate: Following repeated once-daily inhalation in patients with COPD, pharmacokinetic steady-state of glycopyrrolate was reached within 1 week of treatment. There was no indication that the glycopyrrolate pharmacokinetics changes over time. With once-daily doses of 124.8 mcg and 249.6 mcg, steady-state exposure to glycopyrrolate (AUC over the dosing interval) was about 1.4- to 1.7-fold higher than after the first dose.

Distribution

Indacaterol: After intravenous infusion, the volume of distribution (Vz) of indacaterol was 2,361 to 2,557 L, indicating an extensive distribution. The in vitro human serum and plasma protein binding was 94.1% to 95.3% and 95.1% to 96.2%, respectively.

Glycopyrrolate: After intravenous administration, the steady-state volume of distribution (Vss) of glycopyrrolate was 83 L and the volume of distribution in the terminal phase (Vz) was 376 L. The in vitro human plasma protein binding of glycopyrrolate was 38% to 41% at concentrations of 1 to 10 ng/mL.

Metabolism

Indacaterol: In vitro investigations indicated that UGT1A1 is the only UGT isoform that metabolized indacaterol to the phenolic O-glucuronide. The oxidative metabolites were found in incubations with recombinant CYP1A1, CYP2D6, and CYP3A4. CYP3A4 is concluded to be the predominant isoenzyme responsible for hydroxylation of indacaterol. In vitro investigations further indicated that indacaterol is a low affinity substrate for the efflux pump P-gp.

After oral administration of radiolabelled indacaterol in a human ADME (absorption, distribution, metabolism, excretion) study, unchanged indacaterol was the main component in serum, accounting for about one-third of total drug-related AUC over 24 hours. A hydroxylated derivative was the most prominent metabolite in serum. Phenolic O-glucuronides of indacaterol and hydroxylated indacaterol were further prominent metabolites. A diastereomer of the hydroxylated derivative, a N-glucuronide of indacaterol, and C- and N-dealkylated products were further metabolites identified.

Glycopyrrolate: In vitro metabolism studies show glycopyrrolate hydroxylation resulting in a variety of mono- and bis-hydroxylated metabolites and direct hydrolysis resulting in the formation of a carboxylic acid derivative (M9). Further in vitro investigations showed that multiple CYP isoenzymes contribute to the oxidative biotransformation of glycopyrrolate and the hydrolysis to M9 is likely to be catalyzed by members from the cholinesterase family pre-systemically and/or via first pass metabolism from the swallowed dose fraction of orally inhaled glycopyrrolate. Glucuronide and/or sulfate conjugates of glycopyrrolate were found in urine of humans after repeated inhalation, accounting for about 3% of the dose.

Elimination:

Indacaterol: In clinical studies which included urine collection, the amount of indacaterol excreted unchanged via urine was generally lower than 2% of the dose. Renal clearance of indacaterol was, on average, between 0.46 L/h and 1.20 L/h. When compared with the serum clearance of indacaterol of 18.8 L/h to 23.3 L/h, it is evident that renal clearance plays a minor role (about 2% to 6% of systemic clearance) in the elimination of systemically available indacaterol.

In a human ADME study where indacaterol was given orally, the fecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human feces primarily as unchanged parent drug (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose). Mass balance was complete with greater than or equal to 90% of the dose recovered in the excreta.

Indacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing ranged from 40 to 56 hours which is consistent with the observed time to steady-state of approximately 12 to 15 days.

Glycopyrrolate: Renal elimination of parent drug accounts for about 60% to 70% of total clearance of systemically available glycopyrrolate whereas non-renal clearance processes account for about 30% to 40%. Biliary clearance contributes to the non-renal clearance, but the majority of non-renal clearance is thought to be due to metabolism.

Following inhalation of single and repeated once-daily doses between 62.4 mcg and 249.6 mcg glycopyrrolate by healthy volunteers and patients with COPD, mean renal clearance of glycopyrrolate was in the range of 17.4 L/h and 24.4 L/h. Active tubular secretion contributes to the renal elimination of glycopyrrolate.

Glycopyrrolate plasma concentrations declined in a multi-phasic manner. The mean terminal elimination half-life of glycopyrrolate was much longer after inhalation (33 to 53 hours) than after intravenous (6.2 hours) and oral (2.8 hours) administration.

Drug Interactions:

There is no pharmacokinetic drug-drug interaction resulting from the concomitant administration of inhaled glycopyrrolate and inhaled indacaterol based on steady-state exposure data.

No specific drug-drug interaction studies were conducted with indacaterol and glycopyrrolate. Information on the potential for interactions for indacaterol and glycopyrrolate is based on the potential for each of its 2 monotherapy components.

Effect of co-administered drugs on indacaterol and glycopyrrolate exposure:

Indacaterol:

Inhibitors of Cytochrome P450 3A4 and P-gp Efflux Transporter: Drug interaction studies were carried out using potent and specific inhibitors of CYP3A4 and P-gp (i.e., ketoconazole, erythromycin, verapamil and ritonavir). Coadministration of indacaterol 300 mcg (single dose) with verapamil (80 mg 3 times a day for 4 days) showed 2-fold increase in indacaterol AUC0-24h, and 1.5-fold increase in indacaterol Cmax. Coadministration of indacaterol inhalation powder 300 mcg (single dose) with erythromycin (400 mg 4 times a day for 7 days) showed a 1.4-fold increase in indacaterol AUC0-24h, and 1.2-fold increase in indacaterol Cmax. Coadministration of indacaterol inhalation powder 300 mcg (single dose) with ketoconazole (200 mg twice-daily for 7 days) caused a 1.9-fold increase in indacaterol AUC0-24h, and 1.3-fold increase in indacaterol Cmax. Coadministration of indacaterol 300 mcg (single dose) with ritonavir (300 mg twice-daily for 7.5 days) resulted in a 1.7-fold increase in indacaterol AUC0-24h whereas indacaterol Cmax was unaffected.

Glycopyrrolate: Cimetidine or Other Inhibitors of Organic Cationic Transport: In a clinical study in healthy volunteers, cimetidine, an inhibitor of organic cation transport which is thought to contribute to the renal excretion of glycopyrrolate, increased total exposure (AUC) to glycopyrrolate by 22% and decreased renal clearance by 23%.

Effect of indacaterol and glycopyrrolate on co-administered drugs exposure:

In vitro studies show that indacaterol and glycopyrrolate is not likely to inhibit or induce the metabolism of other drugs, nor processes involving drug transporters.

Indacaterol: In vitro investigations indicated that indacaterol has negligible potential to cause metabolic interactions with medications (by inhibition or induction of cytochrome P450 enzymes, or induction of UGT1A1) at the systemic exposure levels achieved in clinical practice. In vitro investigation furthermore indicated that, in vivo, indacaterol is unlikely to significantly inhibit transporter proteins such as P-gp, MRP2, BCRP, the cationic substrate transporters hOCT1 and hOCT2, and the human multidrug and toxin extrusion transporters hMATE1 and hMATE2K, and that indacaterol has negligible potential to induce P-gp or MRP2.

Glycopyrrolate: In vitro inhibition studies demonstrated that glycopyrrolate has no relevant capacity to inhibit CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5, the efflux transporters MDR1, MRP2 or MXR, and the uptake transporters OATP1B1, OATP1B3, OAT1, OAT3, OCT1 or OCT2. In vitro enzyme induction studies did not indicate a clinically relevant induction by glycopyrrolate for any of the cytochrome P450 isoenzymes tested as well as for UGT1A1 and the transporters MDR1 and MRP2.

Specific Populations:

Population pharmacokinetic analysis showed no evidence of a clinically significant effect of age (40 to 85 years), body weight (45 to 120 kg), gender, smoking status, and baseline FEV1 on systemic exposure of either indacaterol or glycopyrrolate following inhalation of indacaterol and glycopyrrolate.

Similarly no relevant covariate effect (of age, body weight, gender, smoking status, and baseline FEV1) was observed following the inhalation of the 2 components indacaterol and glycopyrrolate separately.

Patients with Renal Impairment:

Indacaterol: Due to the very low contribution of the urinary pathway to total body elimination of indacaterol, a study in renally impaired subjects was not performed.

Glycopyrrolate: Renal impairment has an impact on the systemic exposure to glycopyrrolate. A moderate mean increase in total systemic exposure (AUC last) of up to 1.4-fold was seen in subjects with mild and moderate renal impairment [estimated GFR greater than or equal to 30 mL/min/1.73m2] and up to 2.2-fold in subjects with severe renal impairment and end stage renal disease [estimated GFR less than 30 mL/min/1.73m2].

Patients with Hepatic Impairment:

Based on the clinical pharmacokinetic characteristics of its monotherapy components, indacaterol and glycopyrrolate can be used at the recommended dose in patients with mild and moderate hepatic impairment. Indacaterol and glycopyrrolate has not been evaluated in subjects with severe hepatic impairment.

Indacaterol: Patients with mild and moderate hepatic impairment showed no relevant changes in Cmax or AUC of indacaterol, nor did protein binding differ between mild and moderate hepatic impaired subjects and their healthy controls. Studies in subjects with severe hepatic impairment were not performed.

Glycopyrrolate: Clinical studies in patients with hepatic impairment have not been conducted. Glycopyrrolate is cleared predominantly from the systemic circulation by renal excretion.

Ethnicity:

There was no evidence of a clinically significant ethnic/race effect (across Caucasian, Chinese, and Japanese subjects) on the systemic exposure to indacaterol and glycopyrrolate following inhalation of indacaterol and glycopyrrolate. Similarly, no relevant ethnic effect was observed following the inhalation of the 2 components indacaterol and glycopyrrolate separately.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with indacaterol and glycopyrrolate; however, studies are available for the individual components, indacaterol and glycopyrrolate, as described below.

Indacaterol: Indacaterol produced no treatment-related increases in the incidence of tumors in a 2-year inhalation study in Wistar rats at inhaled doses up to 2.09 mg/kg/day (approximately 110 times the MRHD in adults on an AUC basis, respectively). A 26-week oral (gavage) study in CB6F1/TgrasH2 hemizygous mice with indacaterol at doses up to 600 mg/kg/day did not show any evidence of tumorigenicity. Indacaterol tested negative in the following genotoxicity assays: the in vitro Ames test, in vitro chromosome aberration test in V79 Chinese hamster cells, and in vivo rat bone marrow micronucleus test. Indacaterol had no effects on fertility and reproductive performance in male and female rats at subcutaneous doses up to 2 mg/kg/day (approximately 890 and 670 times in males and females, respectively, the MRHD in adults on an AUC basis).

Glycopyrrolate: Glycopyrrolate produced no treatment-related increases in the incidence of tumors in a 2-year inhalation study in Wistar rats at inhaled doses up to 0.56 mg/kg/day (approximately 170 times the MRHD in adults on an AUC basis). A 26-week oral (gavage) study in male and female TgrasH2 mice that received glycopyrrolate at doses up to 93.8 and 125.1 mg/kg/day, respectively, did not show any evidence of tumorigenicity. Glycopyrrolate tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro human lymphocyte chromosomal aberration assay, and in vivo rat bone marrow micronucleus assay. Impairment of fertility was observed in male and female rats at a subcutaneous dose of 1.88 mg/kg/day (approximately 1900 and 1100 times the MRHD in adults on an AUC basis, respectively) based upon findings of decreased corpora lutea, implantation sites and live fetuses. No effects on fertility and reproductive performance in male and female rats were observed at a subcutaneous dose of 0.63 mg/kg/day (approximately 350 times the MRHD in adults on an AUC basis).

Animal Toxicology:

Eye findings were seen for glycopyrrolate and were observed in Wistar rats at inhaled doses of 0.67 mg/kg/day and higher (approximately 280 times the MRHD in adults on an AUC basis) based upon findings of anterior capsule opacity, prominent anterior suture line, and anterior cataract. No eye findings in Wistar rats were observed at an inhaled dose of 0.09 mg/kg/day (approximately 60 times the MRHD in adults on an AUC basis). Eye findings were observed in beagle dogs at an inhaled dose of 0.33 mg/kg/day (approximately 150 times the MRHD in adults on an AUC basis) based upon findings of conjunctival hyperemia and corneal opacity. No eye findings in beagle dogs were observed at an inhaled dose of 0.12 mg/kg/day (approximately 100 times the MRHD in adults on an AUC basis).

Clinical Studies

The safety and efficacy of indacaterol and glycopyrrolate were evaluated in a clinical development program that included 3 dose-ranging trials, 2 lung function trials of 12 weeks duration (placebo-controlled and active-controlled) and a 12-month long-term safety trial. The efficacy of indacaterol and glycopyrrolate is based primarily on the dose-ranging trials in 562 subjects with COPD or asthma and the 2 placebo- and active-controlled confirmatory trials in 2043 subjects with additional support from one active-controlled 12-month trial in 615 subjects with COPD.

Dose-Ranging Trials:

Dose selection for indacaterol and glycopyrrolate for COPD was based on data for the individual components.

Indacaterol: Indacaterol dose selection in indacaterol and glycopyrrolate is based on the registered dose of 75 mcg once-daily and is also supported by a single-dose, multicenter, randomized, double-blind, placebo-controlled, crossover study in asthma evaluating 5 doses of indacaterol in 91 subjects, (37.5 mcg, 55 mcg, 75 mcg, and 150 mcg once-daily (QD), and 27.5 mcg twice-daily (BID)). A dose-related increase in FEV1 AUC0-24h compared with placebo was observed. The differences in change from baseline in FEV1 AUC0-24h after single dosing for the indacaterol 37.5 mcg, 55 mcg, 75 mcg, and 150 mcg once-daily and the 27.5 mcg twice-daily doses compared to placebo were 0.099 L (95% CI: 0.069, 0.128), 0.132 L (0.103, 0.162), 0.143 L (0.114, 0.171), 0.187 L (0.157, 0.216), and 0.121 L (0.092, 0.151), respectively. These results supported the evaluation of indacaterol 27.5 mcg twice-daily in the confirmatory COPD trials. Indacaterol and glycopyrrolate is not indicated for asthma.

This image is provided by the National Library of Medicine

Glycopyrrolate: Dose selection for glycopyrrolate in indacaterol and glycopyrrolate in COPD was supported by a 28-day, randomized, double-blind, placebo-controlled, 2-period, crossover study evaluating 7 doses of glycopyrrolate (15.6 mcg, 31.2 mcg, 62.4 mcg, and 124.8 mcg once-daily and 15.6 mcg, 31.2 mcg, and 62.4 mcg twice-daily) or placebo in 388 subjects with COPD. The differences in trough FEV1 from baseline after 28 days compared to placebo for the 15.6 mcg, 31.2 mcg, 62.4 mcg, and 124.8 mcg once-daily and for 15.6 mcg, 31.2 mcg, and 62.4 mcg twice-daily doses were 0.083 L (95% CI: 0.030, 0.136), 0.098 L (0.048, 0.148), 0.090 L (0.038, 0.142), 0.176 L (0.132, 0.220), 0.139 L (0.089, 0.189), 0.167 L (0.115, 0.219), and 0.177 L (0.132, 0.222), respectively. The dose-ranging results supported the evaluation of glycopyrrolate 15.6 mcg twice-daily in the confirmatory COPD trials.

This image is provided by the National Library of Medicine

Based on the findings from dose-ranging studies of the individual components, a twice-daily dose of indacaterol/glycopyrrolate 27.5 mcg/15.6 mcg was evaluated in the confirmatory COPD trials.

Confirmatory Trials:

The clinical development program for indacaterol and glycopyrrolate included two (Trial 1 and Trial 2) 12-week, randomized, double-blinded, placebo- and active-controlled, parallel-group trials in subjects with COPD designed to evaluate the efficacy and safety of indacaterol and glycopyrrolate; and one 12-month, randomized, double-blind, active-controlled trial (Trial 3) that evaluated bronchodilation and effects on long-term safety.

The 12-week trials evaluated the efficacy of 2038 subjects that had a clinical diagnosis of COPD, were 40 years of age or older, had a history of smoking greater than 10 pack-years, had a post-albuterol FEV1 greater than or equal to 30% and less than 80% of predicted normal values, had a ratio of FEV1/FVC of less than 0.7, and were symptomatic as determined by a Modified Medical Research Council (mMRC) score greater than or equal to 2. Of the 2038 subjects included in the efficacy analysis, 63% were male and 91% were Caucasian. They had a mean age of 63 years and an average smoking history of 47 pack-years, with 52% identified as current smokers, and 46% used concomitant inhaled corticosteroids. At screening, the mean post-bronchodilator percent predicted FEV1 was 55% (range: 29% to 79%), the mean post-bronchodilator FEV1/FVC ratio was 50% (range: 19% to 71%), and the mean percent reversibility was 23% (range: 0% to 144%).

Trial 1 and Trial 2 evaluated indacaterol and glycopyrrolate 27.5 mcg/15.6 mcg twice-daily (BID), indacaterol 27.5 mcg BID, glycopyrrolate 15.6 mcg BID, and placebo BID. The primary endpoint was the change from baseline in FEV1 AUC0-12h following the morning dose at Day 85 (defined as the mean FEV1 change from baseline over 0 to 12 hours divided by 12 hours) compared with placebo, glycopyrrolate 15.6 mcg BID, and indacaterol 27.5 mcg BID. The comparison of indacaterol and glycopyrrolate with indacaterol 27.5 mcg and glycopyrrolate 15.6 mcg was assessed to evaluate the contribution of the individual comparators to indacaterol and glycopyrrolate. In both trials, indacaterol and glycopyrrolate demonstrated a larger increase in mean change from baseline in FEV1 AUC0-12h compared to placebo, indacaterol 27.5 mcg BID, and glycopyrrolate 15.6 mcg BID (see Table 2).

This image is provided by the National Library of Medicine

With the limited data available, there was no suggestion of a difference in FEV1 AUC0-12h with respect to age, sex, degree of airflow limitation, GOLD stage, smoking status, or inhaled corticosteroid use.

In Trial 1 and Trial 2, serial spirometric evaluations throughout the 12-hour dosing interval were performed in all subjects at Days 1 and 85. The spirometric curves from Trial 1 at Days 1 and 85 are displayed in Figure 3. In Trial 2, the results for indacaterol and glycopyrrolate in FEV1 AUC0-12h were similar to those observed in Trial 1.

This image is provided by the National Library of Medicine

The peak FEV1 was defined as the maximum FEV1 recorded within 4 hours after the morning dose on Days 1 and 85. The mean peak FEV1 improvement from baseline for indacaterol and glycopyrrolate compared with placebo at Day 1 and at Day 85 was 0.185 L and 0.290 L (Trial 1) and 0.151 L and 0.260 L (Trial 2), respectively. The median time to onset on Day 1, defined as a 100 mL increase from baseline in FEV1, was 12 minutes and 16 minutes in Trials 1 and 2, respectively, in subjects receiving indacaterol and glycopyrrolate.

In Trials 1 and 2, patients treated with indacaterol and glycopyrrolate used less daily rescue albuterol compared to patients treated with placebo.

The St. George’s Respiratory Questionnaire (SGRQ) was assessed in Trials 1 and 2. In Trial 2, the SGRQ responder rate (defined as an improvement in score of 4 or more as threshold) was 57%, 46%, 48%, and 39%, for indacaterol and glycopyrrolate, glycopyrrolate, indacaterol, and placebo, respectively, with odds ratios of 1.6 (95% CI 1.1, 2.3), 1.5 (95% CI 1.1, 2.2), and 2.2 (95% CI 1.5, 3.2), for indacaterol and glycopyrrolate vs. glycopyrrolate, indacaterol and glycopyrrolate vs. indacaterol, and indacaterol and glycopyrrolate vs. placebo, respectively. In Trial 1, the trends were similar, with odds ratios of 1.4 (95% CI 1.0, 2.0), 1.1 (95% CI 0.8, 1.7), and 2.9 (95% CI 1.9, 4.2), for indacaterol and glycopyrrolate vs. glycopyrrolate, indacaterol and glycopyrrolate vs. indacaterol, and indacaterol and glycopyrrolate vs placebo, respectively.

52-week Effects on Lung Function: At week 52 (Trial 3), indacaterol and glycopyrrolate demonstrated a significant treatment effect with an increase of 0.080 L in pre-dose trough FEV1 compared to indacaterol 75 mcg once-daily.

How Supplied

Indacaterol and glycopyrrolate contains indacaterol and glycopyrrolate (indacaterol/glycopyrrolate, (27.5 mcg, 15.6 mcg) inhalation powder) in hypromellose (HPMC) capsule with yellow transparent cap and uncolored transparent body, with capsules packaged in aluminum blister cards, one NEOHALER device, and an FDA approved Medication Guide.

  • Unit Dose (blister pack), Box of 60 (10 blister cards with 6 yellow transparent capsules each) NDC 0078-0664-19
  • Unit Dose (blister pack), Box of 6 (1 blister card with 6 yellow transparent capsules each) NDC 0078-0664-06

The NEOHALER device consists of a white protective cap and a base with mouthpiece, capsule chamber and 2 yellow push buttons.

Storage

Store in a dry place at 77°F (25°C); excursions permitted to 59°F to 86°F (15°C to 30°C). Indacaterol and glycopyrrolate capsules should be used with the NEOHALER device only. Do not use the NEOHALER device with any other capsules. Store indacaterol and glycopyrrolate capsules in the blister protected from light and moisture. Remove the indacaterol and glycopyrrolate capsules from the blister immediately before use. Always use the new NEOHALER inhaler provided with each new prescription. Keep out of the reach of children.

Images

Drug Images

{{#ask: Page Name::Indacaterol and glycopyrrolate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

This image is provided by the National Library of Medicine
This image is provided by the National Library of Medicine

{{#ask: Label Page::Indacaterol and glycopyrrolate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Precautions with Alcohol

Alcohol-Indacaterol and glycopyrrolate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Indacaterol and glycopyrrolate Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Indacaterol and glycopyrrolate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Retrieved from "https://www.wikidoc.org/index.php?title=Indacaterol_and_glycopyrrolate&oldid=1332079"